For Healthcare Providers

Musculoskeletal adaptations to strength training in frail elderly: a matter of quantity or quality?

S.N. Aas, M. Breit, S. Karsrud, et al.

J Cachexia Sarcopenia Muscle. 2020 Feb 24. doi: 10.1002/jcsm.12543. [Epub ahead of print]

The aim of this study was to investigate the effect of heavy-load strength training on a broad number of factors related to specific strength in frail elderly.

The association between sarcopenia and fracture in middle-aged and elderly people: A systematic review and meta-analysis of cohort studies

H. Chen, J. Ma, A. Liu, et al.

Injury. 2020 Feb 18. pii: S0020-1383(20)30146-7. doi: 10.1016/j.injury.2020.02.072. [Epub ahead of print]

The association between sarcopenia and risk of fracture remained controversial. This systematic review and meta-analysis was conducted to evaluate the association between sarcopenia and fracture incidence in the middle-aged and elderly people.

Which one came first: movement behavior or frailty? A cross-lagged panel model in the Toledo Study for Healthy Aging

A. Mañas, B. Del Pozo-Cruz, I. Rodríguez-Gómez, et al.

J Cachexia Sarcopenia Muscle. 2020 Jan 8. doi: 10.1002/jcsm.12511. [Epub ahead of print]

This study aimed to determine the potential bidirectionality of the relationship between accelerometer-assessed between moderate-to-vigorous physical activity (MVPA), sedentary behaviour (SB), and frailty over time in older adults.

Limitations of SARC-F in the diagnosis of sarcopenia in community-dwelling older adults

T. Kera, H. Kawai, H. Hirano, et al.

Arch Gerontol Geriatr. 2020 Mar - Apr;87:103959. doi: 10.1016/j.archger.2019.103959. Epub 2019 Sep 24.

The SARC-F is a recommended screening tool for sarcopenia; however, its sensitivity is reported to be very low. This study aimed to confirm the diagnostic efficacy of the SARC-F and whether it is affected by population characteristics.

Inflammatory biomarkers of frailty

M. Vatic, S. von Haehling, N. Ebner

Exp Gerontol. 2020;133:110858. doi: 10.1016/j.exger.2020.110858. Epub 2020 Jan 31.

This review summarizes the present knowledge of inflammatory biomarkers that are considered promising tools to evaluate frailty.

ICFSR Task Force Perspective on Biomarkers for Sarcopenia and Frailty

L. Rodriguez-Mañas, I. Araujo de Carvalho, S. Bhasin,et al.

J Frailty Aging. 2020;9(1):4-8. doi: 10.14283/jfa.2019.32.

The International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force - a group of academic and industry scientists from around the world -- met in February 2019 to discuss the current state of biomarker development for frailty and sarcopenia.